Aurobindo PharmaQ1 FY27
Aurobindo Pharma Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,606P/E: 24.9Market Cap: ₹94.2K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →Consolidated revenues increased by 16% YoY to Rs. 9,150 crores, driven by broad-based business performance.
- →Formulation business grew 17% YoY, contributing ~89% of revenues.
- →U.S. revenues up 8.1% YoY with 10 new product launches and 9 ANDA filings in the quarter.
- →European business expects double-digit growth in FY27 with continued new launches.
- →Growth markets increased 38% YoY, with expansion in countries like Indonesia, China, and Canada.
- →FY27 guidance: double-digit revenue growth, EBITDA margins above 21%, EBITDA exceeding Rs. 8,000 crores.
- →Biosimilar and biological CMO businesses are long-term growth drivers.
- →TheraNym CDMO revenues expected to start from 2028 (~$150-$200 million by 2032) with 35-50% EBITDA margins.
- →China facility production doubled, aiming to exceed 2 billion tablets by mid-next year.
- →Strong pipeline execution with multiple near-term product filings, especially in complex respiratory and controlled substance portfolios.
Margin guidance
Category 3- →Aurobindo Pharma expects double-digit revenue growth for FY27, driven by broad-based performance across key markets including the U.S., Europe, and growth markets.
- →EBITDA margins are projected to be north of 21%, with absolute EBITDA exceeding Rs. 8,000 crores in FY27, supported by positive outperformance in high-value strategic areas.
- →Operating leverage and efficient capital management led to a profit after tax of Rs. 1,032 crores in Q1 FY27, reflecting healthy earnings quality.
- →The company is entering a milestone monetization phase for past investments, expected to progressively improve margins, cash generation, and returns on capital over the coming years.
- →Biologics CDMO and biosimilars businesses are anticipated to become important long-term growth drivers beyond the base formulation and API businesses.
- →With strategic investments in complex generics, specialty pharma, injectables, and biologics, Aurobindo is transforming towards higher-quality earnings and stronger free cash flows.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The transcript from page 18 and surrounding pages does not mention any current or planned fundraising through debt or equity.
- →There is no discussion of issuing new shares, raising equity capital, or taking on new debt explicitly during the call.
- →The company noted a strong net cash position of $42 million after payments related to buyback and Lannett acquisition.
- →Focus currently appears to be on capital expenditure funded internally, mainly for TheraNym Biologics.
- →Management emphasized disciplined capital structure and prudent treasury management, suggesting no immediate need for external fundraising.
- →Any future capital requirements appear planned to be met via operational cash flows and internal accruals rather than new fundraising at this stage.
Order book
The transcript provided does not explicitly mention the current or expected order book or pending orders for Aurobindo Pharma Limited as of August 2026. However, relevant insights related to business outlook include:
- European biosimilars commercialization is in early stages with modest, steady progress; three commercial channels are active (Aurobindo Europe, Orion, and STADA partnership).
- The CDMO business revenue is expected to start in 2028 (Unit 1) and 2031 (Unit 2), potentially reaching US$150-200 million by 2032.
- US business shows resilience with continuous product launches and strong pipeline execution.
- Growth markets exhibit strong underlying performance with no specific market dominating.
- R&D and pipeline advancements indicate active development and upcoming product launches.
No direct data on order backlogs or pending orders is provided in the transcript.
Capex plans
Yes- →Net CapEx for the quarter was $78 million, mainly focused on TheraNym Biologics.
- →The Lannett acquisition has provided substantial manufacturing capacity and strategic benefits with minimal additional CAPEX needed in the short term.
- →Aurobindo has scope for expansion at existing facilities, including Lannett and Aurolife units, and has a reserve facility that can be quickly brought online if required.
- →The recent acquisition of A1 Biochem (a CRO) complements existing API capabilities, aiming to develop an integrated CRDMO, accelerating growth by 3-5 times over 3-5 years versus greenfield investment taking 5 years.
- →Focus on backward integration and investment in complex generics, specialty pharmaceuticals, injectables, biologics, and CDMO services to build durable competitive advantages and improve returns.
- →Overall, investments made over the last decade are transitioning from the investment phase to monetization, improving margins, cash flows, and returns on capital.
How does Aurobindo Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Aurobindo Pharma
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does Aurobindo Pharma rank in Pharmaceuticals & Biotechnology?
Compare Aurobindo Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.